Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders

MC Michel, L Cardozo, CJ Chermansky, F Cruz… - Pharmacological …, 2023 - ASPET
Overactive bladder syndrome with and without urinary incontinence and related conditions,
signs, and disorders such as detrusor overactivity, neurogenic lower urinary tract …

Resiniferatoxin: nature's precision medicine to silence TRPV1-positive afferents

A Szallasi - International Journal of Molecular Sciences, 2023 - mdpi.com
Resiniferatoxin (RTX) is an ultrapotent capsaicin analog with a unique spectrum of
pharmacological actions. The therapeutic window of RTX is broad, allowing for the full …

Mechanotransduction in the urothelium: ATP signalling and mechanoreceptors

X Li, J Hu, P Yin, L Liu, Y Chen - Heliyon, 2023 - cell.com
The urothelium, which covers the inner surface of the bladder, is continuously exposed to a
complex physical environment where it is stimulated by, and responds to, a wide range of …

[PDF][PDF] Examination of the effects of botulinum toxin A on bladder sensation

C Dowson - 2023 - kclpure.kcl.ac.uk
Botulinum toxins (Botn) are potent naturally occurring neurotoxins with properties that when
applied in a controlled manner have, for over half a century, been utilised as a therapy for a …

Intravesical drug therapy

JT Purves - Handbook of Neurourology: Theory and Practice, 2023 - Springer
Intravesical drug therapy for neurogenic bladder is currently limited to oxybutynin where
higher drug levels can be achieved with lower side effect profiles than via the oral route. The …